Neoantigen Therapies Global Market Report 2026

Neoantigen therapies are individualized cancer immunotherapy treatments that focus on tumor-specific neoantigens generated through genetic mutations within cancer cells. These therapies combine genomic analysis, bioinformatics tools, and immune engineering approaches to stimulate targeted immune responses against tumors while limiting effects on healthy tissues. Neoantigen therapies are intended to improve treatment precision, enhance anti-tumor effectiveness, and advance personalized cancer care across a range of oncology indications.

The primary therapy types of neoantigen therapies include personalized neoantigen vaccines, off the shelf neoantigen therapies, adoptive T cell therapies, and other therapy types. Personalized neoantigen vaccines refer to patient-specific immunotherapies developed using unique tumor mutations to stimulate targeted anti-cancer immune responses. These therapies utilize technologies including next generation sequencing, bioinformatics, peptide synthesis, and other technologies and are administered through Intravenous, intradermal, and oral routes. They find application in lung cancer, melanoma, colorectal cancer, breast cancer, and others, serving end users including hospitals, cancer research institutes, specialty clinics, and others.

Tariffs are influencing the neoantigen therapies market by increasing costs of imported genomic sequencing instruments, peptide synthesis reagents, and advanced bioinformatics infrastructure required for personalized cancer immunotherapy development. This is raising overall development expenses and slowing research and clinical translation timelines, particularly in import-dependent regions such as Asia-Pacific and Latin America. Equipment- and reagent-intensive segments such as next-generation sequencing platforms and peptide-based neoantigen vaccines are most impacted due to reliance on global supply chains. However, tariffs are also encouraging localized biotech production, regional diversification of suppliers, and increased investment in domestic precision oncology ecosystems, strengthening long-term market resilience.

The neoantigen therapies market size has grown exponentially in recent years. It will grow from $0.96 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 24.1%. The growth in the historic period can be attributed to increasing global cancer incidence rates, advancements in next-generation sequencing technologies, early adoption of personalized medicine approaches in oncology, rising clinical trial activity for immunotherapy treatments, and growing understanding of tumor mutational burden in cancer progression.

The neoantigen therapies market size is expected to see exponential growth in the next few years. It will grow to $2.83 billion in 2030 at a compound annual growth rate (CAGR) of 24.3%. The growth in the forecast period can be attributed to expansion of AI-driven bioinformatics platforms for antigen prediction, increasing regulatory approvals for personalized cancer vaccines, rising investments in precision oncology research pipelines, development of scalable off-the-shelf neoantigen platforms, and growing adoption of combination immunotherapy regimens in clinical oncology. Major trends in the forecast period include expansion of personalized neoantigen vaccine development using tumor-specific mutation profiling, increasing integration of AI-driven neoantigen prediction and epitope mapping for improved immunogenic accuracy, growth of mRNA-based and peptide-based individualized cancer immunotherapies targeting patient-specific tumor signatures, rising adoption of next-generation sequencing-guided precision oncology workflows for early tumor antigen identification, and advancement in combination immunotherapy approaches integrating neoantigen therapies with checkpoint inhibitors for enhanced tumor suppression.

The rising global incidence of cancer is expected to drive the expansion of the neoantigen therapies market in the coming years. Cancer incidence refers to the number of newly diagnosed cancer cases within a defined population over a specified time period, reflecting the increasing global burden of cancer. The growth in cancer incidence is primarily attributed to the aging population, as cancer risk increases with age due to the accumulation of genetic mutations and prolonged exposure to environmental risk factors. Neoantigen therapies contribute to cancer treatment by enabling highly personalized immunotherapy approaches that target tumor-specific mutations, thereby enhancing treatment precision and improving immune response effectiveness. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, it is projected that by 2050, more than 35 million new cancer cases will occur, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising global cancer incidence is driving the growth of the neoantigen therapies market.

Leading companies operating in the neoantigen therapies market are focusing on advancing personalized cancer immunotherapy solutions, such as individualized neoantigen vaccines, to improve tumor-specific immune responses, enhance treatment precision, and support long-term disease control. Individualized neoantigen vaccines refer to customized immunotherapies developed using patient-specific tumor mutation profiles to stimulate targeted immune attacks against cancer cells. For example, in April 2026, Transgene S.A., a France-based biotechnology company, announced the completion of randomization in its Phase II clinical trial evaluating TG4050, a personalized neoantigen therapeutic vaccine developed using its myvac platform. The therapy is designed to generate individualized immune responses against tumor-specific mutations in patients with head and neck cancer, supporting advancements in precision oncology and next-generation cancer immunotherapy development.

In January 2026, BioNTech SE, a Germany-based biotechnology company focused on mRNA-based immunotherapies and cancer treatment development, acquired CureVac N.V. for $5.46 billion. This acquisition strengthens BioNTech SE's oncology and personalized cancer immunotherapy portfolio by expanding its capabilities in mRNA-based neoantigen therapies and individualized cancer vaccine development. CureVac N.V. is a Germany-based biotechnology company specializing in mRNA therapeutics, personalized cancer vaccines, and neoantigen-based immunotherapy platforms.

Major companies operating in the neoantigen therapies market are Moderna Inc., BioNTech SE, Agenus Inc., Immatics N.V., Elicio Therapeutics Inc., Nykode Therapeutics ASA, Creative Biolabs, Advaxis Inc., AIVITA Biomedical Inc., Medigene AG, Nouscom AG, Ultimovacs ASA, Geneos Therapeutics Inc., Treos Bio Limited, TVAX Biomedical Inc., Evaxion Biotech A/S, Circio Holding ASA, Transgene S.A., INTAVIS Peptide Services GmbH, Merck & Co., Bristol Myers Squibb, Roche/Genentech, AstraZeneca, GSK plc

North America was the dominant region in the neoantigen therapies market in 2025. North America is expected to be the rapidly expanding region in the forecast period. The regions covered in neoantigen therapies report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neoantigen therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neoantigen therapies market consists of revenues earned by entities by providing services such as genomic profiling, neoantigen identification, personalized vaccine development, immune cell engineering, clinical trial support, and precision oncology treatment solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The neoantigen therapies market also includes sales of neoantigen peptide vaccines, neoantigen mrna therapeutics, dendritic cell-based immunotherapies, and neoantigen-targeted combination immunotherapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The neoantigen therapies market research report is one of a series of new reports from The Business Research Company that provides neoantigen therapies market statistics, including neoantigen therapies industry global market size, regional shares, competitors with a neoantigen therapies market share, detailed neoantigen therapies market segments, market trends and opportunities, and any further data you may need to thrive in the neoantigen therapies industry. This neoantigen therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neoantigen Therapies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses neoantigen therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neoantigen therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neoantigen therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Therapy Type: Personalized Neoantigen Vaccines; Off The Shelf Neoantigen Therapies; Adoptive T Cell Therapies; Other Therapy Types
• 2) By Technology: Next Generation Sequencing; Bioinformatics; Peptide Synthesis; Other Technologies
• 3) By Route Of Administration: Intravenous; Intradermal; Oral
• 4) By Application: Lung Cancer; Melanoma; Colorectal Cancer; Breast Cancer; Other Applications
• 5) By End User: Hospitals; Cancer Research Institutes; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Personalized Neoantigen Vaccines: Peptide Based Neoantigen Vaccines; Ribonucleic Acid Based Neoantigen Vaccines; Deoxyribonucleic Acid Based Neoantigen Vaccines; Dendritic Cell Neoantigen Vaccines
• 2) By Off The Shelf Neoantigen Therapies: Shared Neoantigen Therapies; Pre Manufactured Cancer Vaccines; Allogeneic Neoantigen Therapies; Multi Target Neoantigen Platforms
• 3) By Adoptive T Cell Therapies: Tumor Infiltrating Lymphocyte Therapies; T Cell Receptor Engineered Therapies; Chimeric Antigen Receptor T Cell Therapies; Neoantigen Reactive T Cell Therapies
• 4) By Other Therapy Types: Combination Immunotherapies; Oncolytic Virus Based Neoantigen Therapies; Checkpoint Inhibitor Combination Therapies; Experimental Neoantigen Platforms
• Companies Mentioned: Moderna Inc.; BioNTech SE; Agenus Inc.; Immatics N.V.; Elicio Therapeutics Inc.; Nykode Therapeutics ASA; Creative Biolabs; Advaxis Inc.; AIVITA Biomedical Inc.; Medigene AG; Nouscom AG; Ultimovacs ASA; Geneos Therapeutics Inc.; Treos Bio Limited; TVAX Biomedical Inc.; Evaxion Biotech A/S; Circio Holding ASA; Transgene S.A.; INTAVIS Peptide Services GmbH; Merck & Co.; Bristol Myers Squibb; Roche/Genentech; AstraZeneca; GSK plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.